Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.

Elizondo CR, Bright JD, Byrne JA, Bright RK.

Hum Vaccin Immunother. 2019 Nov 26:1-11. doi: 10.1080/21645515.2019.1689746. [Epub ahead of print]

PMID:
31769704
2.

Delayed recruiting of TPD52 to lipid droplets - evidence for a "second wave" of lipid droplet-associated proteins that respond to altered lipid storage induced by Brefeldin A treatment.

Chen Y, Frost S, Khushi M, Cantrill LC, Yu H, Arthur JW, Bright RK, Groblewski GE, Byrne JA.

Sci Rep. 2019 Jul 5;9(1):9790. doi: 10.1038/s41598-019-46156-1.

3.

Enhanced capture and release of circulating tumor cells using hollow glass microspheres with a nanostructured surface.

Dong Z, Yu D, Liu Q, Ding Z, Lyons VJ, Bright RK, Pappas D, Liu X, Li W.

Nanoscale. 2018 Sep 13;10(35):16795-16804. doi: 10.1039/c8nr04434a.

4.

TPD52 expression increases neutral lipid storage within cultured cells.

Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, Bright RK, Groblewski GE, Straub BK, Hoy AJ, Chen Y, Byrne JA.

J Cell Sci. 2015 Sep 1;128(17):3223-38. doi: 10.1242/jcs.167692. Epub 2015 Jul 16.

5.

Overexpressed oncogenic tumor-self antigens.

Bright RK, Bright JD, Byrne JA.

Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475. Review.

6.

Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Byrne JA, Frost S, Chen Y, Bright RK.

Tumour Biol. 2014 Aug;35(8):7369-82. doi: 10.1007/s13277-014-2006-x. Epub 2014 May 6. Review.

PMID:
24798974
7.

Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.

Bright JD, Schultz HN, Byrne JA, Bright RK.

Oncoimmunology. 2013 Jul 1;2(7):e25049. Epub 2013 May 21.

8.

TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.

Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA.

Mol Carcinog. 2014 Oct;53(10):807-19. doi: 10.1002/mc.22038. Epub 2013 May 9.

PMID:
23661506
9.

A growing role for hypertrophy in senescence.

Wright J, Dungrawala H, Bright RK, Schneider BL.

FEMS Yeast Res. 2013 Feb;13(1):2-6. doi: 10.1111/1567-1364.12015. Epub 2012 Nov 23. No abstract available.

10.

The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen.

Aldrich JF, Shearer MH, Lowe DB, Winn RE, Jumper CA, Kennedy RC, Bright RK.

Cancer Immunol Immunother. 2013 Feb;62(2):371-82. doi: 10.1007/s00262-012-1338-x. Epub 2012 Aug 25.

PMID:
22926061
11.

CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Bright RK, Kennedy RC.

J Virol. 2011 Jul;85(14):7216-24. doi: 10.1128/JVI.00543-11. Epub 2011 May 18.

12.

Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC.

J Virol. 2010 Jan;84(2):883-93. doi: 10.1128/JVI.01512-09. Epub 2009 Nov 4.

13.

Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.

PMID:
19169682
14.

Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.

Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA.

Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.

15.

Evidence of simian virus 40 exposure in a colony of captive baboons.

Westfall LW, Shearer MH, Jumper CA, White GL, Papin JF, Eberle R, Butel JS, Bright RK, Kennedy RC.

Virology. 2008 Jul 20;377(1):54-62. doi: 10.1016/j.virol.2008.03.035. Epub 2008 May 16.

16.

Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.

Payton LA, Lewis JD, Byrne JA, Bright RK.

Cancer Immunol Immunother. 2008 Jun;57(6):799-811. Epub 2007 Oct 26.

PMID:
17962942
17.

Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.

Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK.

Mol Cancer Res. 2007 Feb;5(2):133-44.

18.
19.

Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.

Lewis JD, Shearer MH, Kennedy RC, Bright RK.

Cancer Res. 2005 Apr 1;65(7):2938-46.

20.

In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization.

Lowe DB, Shearer MH, Tarbox JA, Kang HS, Jumper CA, Bright RK, Kennedy RC.

Virology. 2005 Feb 5;332(1):28-37.

21.

Cancer immunotherapy: avoiding the road to perdition.

Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W.

J Transl Med. 2004 Jul 29;2(1):26.

22.

Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity.

Kennedy RC, Shearer MH, Lowe DB, Jumper CA, Chiriva-Internati M, Bright RK.

Cancer Immunol Immunother. 2004 Nov;53(11):987-94. Epub 2004 May 19.

PMID:
15156293
23.

Sperm protein 17 is expressed in human somatic ciliated epithelia.

Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N, Kast WM.

J Histochem Cytochem. 2004 Apr;52(4):549-54.

PMID:
15034007
24.

Tumor-associated antigens: from discovery to immunity.

Lewis JD, Reilly BD, Bright RK.

Int Rev Immunol. 2003 Mar-Apr;22(2):81-112. Review.

PMID:
12962271
25.

Is sperm protein 17 a useful target for tumor immunotherapy?

Chiriva-Internati M, Grizzi F, Franceschini B, Hermonat PL, Bright RK, Bumm K, Dioguardi N, Kast WM.

Blood. 2003 Sep 15;102(6):2308-9. No abstract available.

PMID:
12959941
26.
28.

SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.

Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI.

Cancer Immunol Immunother. 2002 Feb;50(12):682-90. Epub 2001 Dec 13.

PMID:
11862420
30.
31.

Novel molecular and immunotherapeutic strategies for lung cancer.

Pass HI, Kalemkerian G, Bright RK.

Chest Surg Clin N Am. 2001 Feb;11(1):189-212, ix. Review.

PMID:
11253598
32.

Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts.

Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ, Magun BE.

Mol Cell Biol Res Commun. 2000 Aug;4(2):122-8.

PMID:
11170843
33.

Regulated CYP19 aromatase transcription in breast stromal fibroblasts.

Pauley RJ, Santner SJ, Tait LR, Bright RK, Santen RJ.

J Clin Endocrinol Metab. 2000 Feb;85(2):837-46.

PMID:
10690899
34.

Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.

Housseau F, Bright RK, Simonis T, Nishimura MI, Topalian SL.

J Immunol. 1999 Dec 1;163(11):6330-7.

35.

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI.

Br J Cancer. 1999 Sep;81(1):54-61.

36.

Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line.

Virgin JB, Hurley PM, Nahhas FA, Bebchuk KG, Mohamed AN, Sakr WA, Bright RK, Cher ML.

Prostate. 1999 Sep 15;41(1):49-57.

PMID:
10440875
37.

Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.

Ohta Y, Shridhar V, Kalemkerian GP, Bright RK, Watanabe Y, Pass HI.

Cancer. 1999 Jun 15;85(12):2570-6.

PMID:
10375104
38.
39.

Immunotherapy of SV40 induced tumours in mice: a model for vaccine development.

Bright RK, Shearer MH, Pass HI, Kennedy RC.

Dev Biol Stand. 1998;94:341-53.

PMID:
9776255
40.

Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens.

Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL.

Cancer Res. 1997 Mar 1;57(5):995-1002.

41.
42.

Nucleic acid vaccination against virally induced tumors.

Bright RK, Shearer MH, Kennedy RC.

Ann N Y Acad Sci. 1995 Nov 27;772:241-51.

PMID:
8546399
43.

Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen.

Bright RK, Shearer MH, Kennedy RC.

Cancer Immunol Immunother. 1995 Mar;40(3):206-11.

PMID:
7728780
44.
45.
48.

A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein.

Sadziene A, Jonsson M, Bergström S, Bright RK, Kennedy RC, Barbour AG.

Infect Immun. 1994 May;62(5):2037-45.

50.

Supplemental Content

Loading ...
Support Center